ARCUTIS
“ Even with these challenges, Arcutis has three FDA approved products and a robust pipeline with multiple clinical programmes for a range of inflammatory dermatological conditions. The incorporation of AI into our processes will only further accelerate our progress,” says Rajvir.
Rajvir highlights AI in this light as a true gamechanger for the drug discovery and development processes.
“ First of all, it will help when predicting efficacy and the safety profiles of specific drugs,” he explains.“ But I think it’ s also going to help to identify patients likely to succeed on a specific drug. By doing that, they can bring the right patients into clinical trials so that they maximise the benefit for the patients and ultimately for the pharma company as well.”
Another challenge involved after this is the process of filing for regulatory approvals, with Rajvir explaining it typically takes companies anywhere from six to nine months to put a regulatory submission together in the US for the FDA. This process involves extensive data, content development and process management- which all could be streamlined through AI.
“ The faster you file a regulatory submission, the faster you get FDA approval, which means the faster you can get your product into a commercial stage,” he adds“
16 arcutis. com